Results 251 to 260 of about 18,416,887 (403)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) [PDF]

, 2015
David Casadevall, Javier Gimeno, Sergi Clavé, Álvaro Taus, Lara Pijuán, Míriam Arumí, Marta Lorenzo, Sílvia Menéndez, Israel Cañadas, Joan Albanell, Sérgio Serrano, Blanca Espinet, Marta Salido, Edurne Arriola   +13 more
openalex   +1 more source

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.

Cancer Cell, 2016
A. Becker, B. K. Thakur, Joshua M. Weiss, Han Sang Kim, H. Peinado, D. Lyden   +5 more
semanticscholar   +1 more source

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

Cell, 2021
Si Cheng, Ziyi Li, Ranran Gao, B. Xing, Yu-nong Gao, Y. Yang, Shishang Qin, Lei Zhang, Hanqiang Ouyang, Peng Du, Liang Jiang, Bin Zhang, Yue Yang, Xiliang Wang, Xianwen Ren, J. Bei, Xueda Hu, Z. Bu, J. Ji, Zemin Zhang   +19 more
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives. [PDF]

Mar Drugs
Zimmerly JM, Armstrong NA, Euteneuer CF, Davis BN, Griffis-Anchala MB, Vargas A, Davis PH.   +6 more
europepmc   +1 more source

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Science, 2015
N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. Havel, William Lee, Jianda Yuan, P. Wong, Teresa Ho, Martin L. Miller, N. Rekhtman, A. Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, R. Zappasodi, Y. Maeda, C. Sander, E. Garon, T. Merghoub, J. Wolchok, T. Schumacher, T. Chan   +23 more
semanticscholar   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Unlocking Lung Cancer Cell Dormancy: An Epigenetic Perspective. [PDF]

Int J Mol Sci
Fabrizio FP.
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Targeting Lung Cancer Cell Motility Using Microbeam Radiation Therapy. [PDF]

Cells
Dağkazanlı Ö, Čolić A, Lindner R, Bartzsch S, Combs SE, Schmid TE, Franco MS.   +6 more
europepmc   +1 more source